Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

An investigational extended-release formulation of minoxidil appears to result in more hair growth in a small phase 2 trial comparing it with immediate-release oral and topical formulations.

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

Finance is fast becoming one of the most high-impact areas for AI adoption. From anomaly detection to predictive compliance, today’s AI-powered tools help turn complexity into easily digestible data ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Their research led to the development of a drug that nearly doubles the life expectancy for adult cystic fibrosis patients.

AI shifts from promise to practice when customization becomes routine. That is a positive sign. When technical teams work with data as it is, measure progress with discipline, and focus on workflows ...

Cerebras’s hosted Qwen3 Coder service promised to be the Claude replacement many developers craved. We’re losing hope.

We'll compare five of the best IDP platforms available in 2025, covering what they do well, where they may fall short, and ...

For CTOs and senior technology leaders, cloud cost optimization is no longer a back-office exercise—it’s a boardroom priority ...

Healthy teams aren't a nice-to-have. They are a business imperative. Research shows that unhealthy teams cost companies through burnout, lost produ ...

Clemens Fischer has never smoked pot in his life, but he believes his new experimental drug could reap billions in sales—and ...